Vaxart Return on Equity

Vaxart (VXRT) currently reports a ROE of 46.85%. That is above the Healthcare sector average of 11.15%. Use the charts on this page to explore Vaxart's ROE history and peer comparisons.

Vaxart's ROE of 46.85% is higher than the Healthcare sector average of 11.15%. That is roughly 320.0% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Vaxart's current 46.85% should be judged against Healthcare norms (sector average: 11.15%) and against VXRT's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 46.85%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for Vaxart, and consider following VXRT for alerts when major investors trade the stock.

Vaxart is classified in the Healthcare sector. On ROE, it currently shows 46.85% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing VXRT with unrelated industries.